Related Experiment Video
Updated: Jan 9, 2026

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
Published on: November 29, 2024
Dulaglutide as a Bridging Therapy Before Insulin for Diabetes Following Pancreatectomy on Congenital Hyperinsulinism
Sakura Motegi1, Masanori Adachi1, Keiko Nagahara1
1Department of Pediatrics, Showa Medical University, Tokyo 142-8666, Japan.
Abstract:
Hyperinsulinism and postpancreatectomy diabetes (CHI/PPD) refers to diabetes following pancreatectomy to treat hypoglycemia due to congenital hyperinsulinism. Insulin therapy in CHI/PPD may sometimes be challenging because of glucagon deficiency and the dysfunction of the remaining β-cells. In a 16-year-old male patient with CHI/PPD and severe hypoglycemic brain damage, a dulaglutide trial was planned, because some biochemical indices suggested that he was not completely insulin-dependent. Other than transient appetite loss, no adverse events were observed. The patient's hemoglobin A1c level promptly decreased from 6.7% (SI: 49.7 mmol/mol) [reference range, 4.6-6.2% (SI: 26.8-44.3 mmol/mol)] to 5.7%, with temporary, but not persistent, improvement in endogenous insulin secretion. He has been free from exogenous insulin for more than 4 years under dulaglutide. In conclusion, in selected patients with CHI/PPD and reserved β-cell function, dulaglutide may serve as a bridging therapy before insulin introduction.
Related Concept Videos
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Oral Hypoglycemic Agents: Glinides
Dipeptidyl Peptidase 4 Inhibitors
Insulin: Biosynthesis, Chemistry, and Preparation
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Chronic Pancreatitis II: Collaborative Care
Assessment:

